Former President Trump stated on Truth Social that imported generic drugs will face a 100 percent tariff beginning in August 2028 unless manufacturers relocate production to the United States. The announcement, aimed at reshoring pharmaceutical manufacturing, prompted an immediate decline in shares of generic-drug makers. Analyses from progressive, conservative, libertarian, and critical viewpoints differ on the policy's effects on costs, supply security, and market dynamics.